2,561 reports of this reaction
16.9% of all GLECAPREVIR AND PIBRENTASVIR reports
#1 most reported adverse reaction
FATIGUE is the #1 most commonly reported adverse reaction for GLECAPREVIR AND PIBRENTASVIR, manufactured by AbbVie Inc.. There are 2,561 FDA adverse event reports linking GLECAPREVIR AND PIBRENTASVIR to FATIGUE. This represents approximately 16.9% of all 15,159 adverse event reports for this drug.
Patients taking GLECAPREVIR AND PIBRENTASVIR who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a frequently reported adverse event for GLECAPREVIR AND PIBRENTASVIR, accounting for a significant proportion of all reports.
In addition to fatigue, the following adverse reactions have been reported for GLECAPREVIR AND PIBRENTASVIR:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 2,561 FDA reports for GLECAPREVIR AND PIBRENTASVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 16.9% of all adverse event reports for GLECAPREVIR AND PIBRENTASVIR, making it one of the most commonly reported side effect.
If you experience fatigue while taking GLECAPREVIR AND PIBRENTASVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.